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Abstract 
 
Background: Meso-tetra-hydroxyphenyl-chlorine (mTHPC) is among the most powerful 
photosensitizers available for photodynamic therapy (PDT). However, the mechanisms 
leading to cell death are poorly understood. We here focuse on changes at DNA and RNA 
levels after treatment with the liposomal mTHPC derivative Foslipos in-vitro.   
Methods: After determination of darktoxicity, laser conditions and uptake kinetics, PC-3 
prostate carcinoma cells were subjected to PDT with Foslipos, followed by assessment of 
cell numbers directly (TP0) or 1h (TP1), 2h (TP2), 5h (TP5) and 24h (TP24) after 
illumination. Nucleic acids had been extracted for evaluation of RNA amounts and 
integrity as well as for estimation of abasic sites as a measure for DNA damage. 
Furthermore, expression changes of 84 genes related to oxidative stress were investigated 
by quantitative polymerase chain reaction.   
Results: Already at TP0, the number of dead cells was significantly higher after PDT 
versus controls and at TP24 more than 90% of cells had been destroyed. PDT resulted in 
a severe damage of both RNA and DNA. Gene expression analyses revealed an impact of 
PDT on pathways for oxidative and metabolic stress, heat shock, proliferation and 
carcinogenesis, growth arrest, inflammation, DNA repair and apoptosis signaling.  
Conclusions: Mechanisms of Foslipos-mediated PDT comprise a combination of acute 
and delayed lethal effects in PC-3 cells. The latter may include death processes initiated 
by nucleic acid damage, activation of stress and growth arrest genes in combination with 
a reduced capability to adequately cope with oxidative toxicity. Our results will help to 
better understand molecular photodynamic effects. 
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Introduction 
Currently, one of the most powerful second-generation photosensitizers available for 
photodynamic therapy (PDT) is meso-tetra-hydroxyphenyl-chlorine (mTHPC, 
Temoporfin), a member of the chlorin family of photosensitizers. The commercial 
product Foscan gained approval in the EC for palliative PDT treatment of patients with 
recurrent or refractory head and neck cancers, but it is also under investigation as a 
promising therapeutic modality for early cancers of the head and neck region, colon 
adenocarcinoma, non-melanotic skin tumors, pleural mesothelioma, pancreas cancer, 
hepatoma, carcinoma in-situ of the vulva, malignant brain tumors, ovarian neoplasms, 
and organ confined prostate cancer [1, 2].  
However, Foscan is highly hydrophobic and thus requires the use of organic solvents like 
alcohols, acetone or ethyl acetate. After intravenous injection in patients, mTHPC 
molecules tend to aggregate and display very complex biokinetics, such as e.g. a series of 
subsequent concentration maxima in plasma or limitations in transportation and tumor-
uptake [3, 4]. In recent years, these clinically unfavorable characteristics prompted the 
development of new derivatives of Temoporfin, including the liposomal formulations 
Foslip and Fospeg (the latter being PEGylated). In addition to the advantage of solvency 
in hydrophilic media, in first in-vivo and in-vitro studies liposome-incorporated mTHPC 
had been shown to accumulate faster, selectively and with higher fluorescence in tumor 
tissues [5-8].  
The cell death pathways evoked by oxidative damage in mTHPC-mediated PDT are far 
from being clear and appear to depend not only on cell type investigated but also on PDT 
protocol. It had been reported that apoptotic pathways may be initiated [9-12], however, 
autophagy or necrosis  [13] may prevail – especially if high PDT doses are applied [14]. 
To date only a limited number of studies are available that focus on the spectrum of 
signaling pathways affected in the course of mTHPC-mediated PDT. Apparently, effects 
may not only include activation of caspase cascades  [10, 11] but also acute-phase 
response processes [15], and expression changes of heat-shock proteins [16], hypoxia-
markers [17], matrix metalloproteinases [18] or cytokines [19]. Since some of these 
cellular responses may modify, delay or even counteract cell death mechanisms, detailed 
analyses are highly needed.    
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With the aim to elucidate pathways leading to and/or interfering with cell death in PDT 
procedures with liposomal mTHPC we here focus on changes at the DNA and RNA 
level, as well as on gene expression profiles, using the established prostate carcinoma cell 
line PC-3 as model system.  
 
Material and Methods 
Cell line and reagents  
The androgen-independent human prostate carcinoma cell line PC-3 was obtained from 
the European Collection of Cell Cultures (ECACC). Cells were grown in DMEM+ (1:1 
mixture of DMEM and Ham’s F-12, without phenol red indicator and pyridoxal HCl, 
supplemented with 10% fetal calf serum and 1% Penicillin-Streptomycin, 10.000 UI/ml, 
all purchased from Gibco, Basel, Switzerland) at 37°C and 5% CO2 in a humid 
environment. Cells were passaged by trypsinization using 1x trypsin/EDTA (Invitrogen, 
Basel, Switzerland). As photosensitizer, we used mTHPC encapsulated into 
dipalmitoylphosphatidylcholine/dipalmitoylphosphatidylglycerol (DPPC/DPPG) 
liposomes (Foslipos, Biolitec AG, Jena, Germany). Unless otherwise stated, chemicals 
were purchased from Sigma, Buchs, Switzerland.  
Dark toxicity assay 
PC-3 cells were plated at a density of 1000 cells per 60 mm Petri dish and allowed to 
attach for 24 h. Thereafter, Foslipos was added to end concentrations of 0.1, 0.5, 1.0, 5.0, 
and 10.0 μg/ml, respectively, and incubated for 5h. Then a colony forming assay was 
performed as described earlier [20]. Briefly, after treatment, cells were washed with PBS 
and fresh DMEM+ was added. Cells were cultured for another 10 days and colonies were 
fixed, stained with azur-methylenblue-Giemsa and counted, whereby only colonies 
containing ≥50 cells were considered. Controls were run under the same conditions, 
while Foslipos was omitted.  
Selection of laser intensity 
PC-3 cells were processed as for the dark toxicity assay described above with the 
exception that cells were exposed to laser light after the 5 h incubation period with 
Foslipos. Laser intensities of 1, 3, and 5 J/cm
2
, respectively, were applied, using a diode 
laser (Applied Optronics Corporation, USA) at 652 nm and a powermeter (Lightwave 
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OMM6810B, GMP, Renens, Switzerland). After irradiation, colony forming assays were 
carried out as described above. 
Confocal laser scanning microscopy 
PC-3 cells grown on cover slips were incubated with 5 μg/ml Foslipos for 15 min, and 1, 
2, 3, 4, and 5 hours, respectively. After a buffer wash, cells were fixed with 4% buffered 
paraformaldehyde, again washed, coverslipped with Glycergel (Dako, Baar, Switzerland) 
and analyzed with a confocal laser scanning microscope (SP2, Leica Microsystems, 
Heerbrugg, Switzerland), using an excitation wavelength of 488nm and detection 
wavelengths of 580-660nm.  
Cell culture treatment 
PC-3 cells were plated at a density of 1x10
6
, allowed to recover for 24 h and treated with 
Foslipos for 5 h at an end concentration of 5 μg/ml. Cells were then exposed to 652 nm 
laser light reaching a dose of 1 J/cm
2
. This experimental setting was termed PDT. Three 
series of controls were included: (1) omission of the photosensitizer, i.e. replacement of 
the photosensitizer by buffer, but inclusion of irradiation (IRR), (2) omission of the 
irradiation and treatment with Foslipos (FOS) and (3) omission of both photosensitizer 
and irradiation (CO).  
After washing all samples with PBS, fresh DMEM+ medium was added and the dishes 
were placed back in the incubator. Experiments were stopped immediately (i.e. after 
about 3-4 min) or after 1, 2, 5, and 24 h, respectively, by 2 x 3 min washing and 5 min 
trypsinization. These five time points are refered to as TP0, TP1, TP2, TP5 and TP24. 
After centrifugation at 1000 rpm for 5 min, cell pellets were resuspended in 1 ml PBS 
and either directly used for cell counting or frozen for later nucleic acid analyses.  
Cell survival test 
Resuspended cells (10 μl) from experimental settings described in “cell culture 
treatment” were mixed with equal volumes of trypan blue solution (0.5%, Serva, Buchs, 
Switzerland) and cells (dead and alive) were immediately counted in a Neubauer 
chamber.  
Nucleic acid extractions and quality analyses 
From the remainder of resuspended cells (i.e. 990 μl), genomic DNA and total RNA was 
extracted with the NucleoSpin RNA II kit in conjunction with the NucleoSpin RNA/DNA 
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buffer set (Macherey-Nagel, Oensingen, Switzerland), following the protocol of the 
manufacturer. The kit allows for a sequential elution of DNA and RNA from the same 
cell lysate using a silica membrane filter column and a set of predesigned buffers. Final 
elution volumes per sample for genomic DNA and total RNA were 100 μl and 60 μl, 
respectively. Nucleic acid concentrations were determined with a Nanodrop 
spectrophotometer (ND-1000, Wilmington, DE).  
RNA quality was assessed by means of the Agilent 2100 Bioanalyzer equipped with the 
RNA integrity number (RIN) software algorithm (Agilent, Waldbronn, Germany). For 
this purpose, total RNA was assayed with the Eukaryote total RNA Nano LabChip kit 
(Agilent) according to the manufacturer’s instructions.  
DNA quality was determined with the DNA Damage Quantification kit (MBL, Woburn, 
MA), that measures the number of apurinic/apyrimidinic sites in DNA lesions. Following 
the recommendations of the manufacturer, genomic DNA was diluted to 100 μg/ml and 
labelled with the biotinylated aldehyde reactive probe provided with the kit. Tagged 
DNA and a tagged standard (provided with the kit) was then bound to a 96-well 
microplate, followed by an avidin-biotin assay and colorimetric detection at O.D.460nm. 
The number of abasic sites within the genomic DNA was determined by comparison with 
the standard curve. 
Gene expression analyses 
For gene expression analyses, the PAHS-003 RT
2
 Profiler PCR array system was 
performed according to instructions of the manufacturer (Human stress and toxicity 
pathways finder array, SuperArray, Frederick, MD). Briefly, 0.5 µg total RNA each from 
samples TP1 (PDT and CO) and TP5 (PDT and CO) were reverse transcribed with the 
RT
2
 First Strand kit (SuperArray). Resulting cDNA was subjected to quantitative PCR 
(qPCR) on an ABI 7500 sequence detection system (Applied Biosystems, Rotkreuz, 
Switzerland) using the supplied 96-well plate format with pre-dispensed specific primer 
sets and the RT
2
 SYBR green/ROX qPCR master mix (SuperArray). Cycling parameters 
were as follows: 1 cycle for 10min at 95°C and 40 cycles of 15sec at 95°C and 1min at 
60°C. Both threshold and baseline values were automatically obtained by the SDS 
software (Applied Biosystems) and CTs for all wells were exported to the company’s 
data analysis web tool (www. superarray.com).  
 7 
Statistical analyses 
All experiments were carried out in triplicate. Statistical analyses were performed with 
the StatView software (www.statview.com). All possible pairwise differences between 
time points as well as between experimental conditions were examined by Fisher’s 
Protected Least Significant Difference (PLSD) tests. P-values less than 0.05 were 
considered significant.  
 
Results 
Experimental conditions 
With the aim to establish the appropriate experimental conditions, we first determined the 
maximal non dark-toxic concentration of Foslipos. We found that colony numbers after 
treatment with 10 μg/ml Foslipos were significantly lower compared to untreated controls 
(p<0.0001), while all other concentrations of Foslipos used showed no statistically 
significant effects compared to controls (fig. 1). We thus decided to perform further 
experiments with 5 µg/ml Foslipos end concentration in the medium. We next 
investigated the conditions of light exposure with minimal lethal effect at 5 μg/ml 
Foslipos. 1 J/cm
2 
showed the lowest phototoxic effect (data not shown) and was thus 
choosen for our further study.  
Microscopy 
Cellular uptake kinetics of Foslipos in PC-3 cells were evaluated on the basis of its 
intracellular fluorescence (fig. 2). Already after 15 min, a weak signal was detectable 
within cells. The fluorescence intensity increased steadily over time, reaching a 
maximum at 4h. It was always diffusely distributed throughout the cytoplasm, with a 
tendency for a higher signal accumulation in the vicinity of the nucleus. However, the 
nuclear compartement itself always remained non-fluorescent (fig. 2).  
PDT-effects on cell death 
As shown in fig. 3, up from the earliest time point investigated (TP0), PDT samples 
contained statistically significant more dead cells than untreated controls (p=0.0002), 
with a death of about 43% of cells compared to CO. The number of dead cells in PDT 
samples, however, remained constant up to TP5, while in the TP24-samples this 
parameter significantly rose (p<0.0001) compared to time points before. At TP24, PDT 
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samples contained only 9% of living cells found in CO. The number of dead cells in IRR 
and FOS was uniformely low and not statistically different from CO at all time points 
investigated.  
Effects on nucleic acid  quantitiy and integrity  
Genomic DNA damage was estimated by measuring the amount of apurinic/apyrimidinic 
sites – a marker for oxidative stress (fig. 4). We found that at all time points measured 
(TP0, TP1, TP24), the degree of oxidative DNA damage was significantly higher in PDT-
treated cells compared to CO samples (TP0, p<0.0001; TP1, p<0.0001; TP24, p<0.0001). 
DNA quality was also impaired in FOS and IRR samples (compared to CO), however, 
the difference between PDT and FOS or IRR was still statistically significant at all time 
points measured (in all cases: p<0.0001). Generally, DNA damage of PDT-treated cells 
was always high, corresponding to an average of 22 abasic sites per 10
5
 base pairs at TP0, 
18 sites per 10
5
 base pairs at TP1 and 16 sites per 10
5
 base pairs at TP24.   
At all time points investigated, absolute amounts of total RNA in PDT samples were 
significantly lower than in CO samples. Being stable until (and including) TP2, RNA 
amounts in PDT samples significantly decreased at TP5, followed by an additional drop 
at TP24 (p=0.0009 and 0.0097, respectively). FOS samples contained RNA amounts 
comparable to those of CO samples, while IRR samples had a significantly higher RNA 
content up from TP1 compared to CO. In all control reactions, significant increases in 
total RNA amounts were found between TP5 and TP24 (IRR: p<0.0001; FOS: p=0.009; 
CO: p=0.0065). When expressed as a ratio of RNA per (living) cell, RNA content per 
PDT-treated cell was significantly lower compared to CO from TP0 on (p=0.0248), but 
then remained unchanged over all time points investigated (fig. 5). In CO and FOS the 
ratio of RNA per cell was comparable and remained constant over time, while IRR 
samples had significantly more RNA per cell at TP5 compared to CO (p<0.0001, fig. 5).  
In contrast to all controls, RNA quality was clearly affected by PDT treatment. A small, 
but statistically significant RNA degradation was already seen at TP0, while RNA 
integrity was completely maintained under all control conditions (RNA integrity number, 
RIN, of CO vs. PDT: p= 0.0022; IRR vs. PDT: p=0.001; FOS vs. PDT: p=0.001). In plus, 
RNA continued to significantly deteriorate over time after PDT, being significantly worse 
compared to controls at all time points measured (fig. 6).  
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Effects on gene expression profiles 
With the aim to further characterize the effects of Foslipos-mediated PDT, we 
investigated the expression of 84 genes involved in stress and toxicity pathways by qPCR 
at TP1 and TP5. Taken together, we found that roughly 57% of all genes investigated 
changed at least two-fold in expression after PDT. Of these, the majority showed reduced 
transcript numbers at TP1 (about 83%). Over time, most of the regulated genes (about 
54%) maintained their initially changed expression levels. However, at TP5 vs. TP1, 
about 23% had been further downregulated (HSPA4, CCNC, CCND1, E2F1, NFKB1, 
ATM, DDB1, BCL2L1, CASP8, CASP10, FASLG), about 12% displayed an further 
upregulation (CRYAB, DNAJB4, HSPA1A, HSPA1L, HSPA6), and about 10% showed 
signs of recovery (GSTM3, HSPA2, ERCC3, RAD50, TNFRSF1A, TNFSF10). Tables 
1-7 summarize those genes whose expression changed more than twofold between CO 
vs. PDT and/or over time.  
In addition, we found that the following genes are expressed in PC-3 but do not appear to 
be regulated after PDT: CYP2E1, GPX1, MT2A, PRDX1, DNAJA1, HSF1, HSPA8, 
HSPB1, HSP90AA2, HSPH1, MIF, GADD45A, GDF15, TP53, CSF2, IL1A, IL6,  
SERPINE1, CHEK2, ANXA5, and NFKBIA. Genes not expressed in PC-3 cells (neither 
CO nor PDT) comprise: CRP1A1, CYP7A1, EGR1, EPHX2, FMO1, PTGS1, CCL3, 
CCL4, CCL21, CXCL10, NOS2A, UGT1A4, CASP1, LTA, and TNF. All gene names 
are designated according to the HUGO gene name nomenclature (www.genenames.org). 
 
Discussion 
Several new strategies are currently under development aiming to improve the efficiency 
and specificity of PDT. In this context, liposomal photosensitizer preparations are of 
interest mainly for two reasons: on the one hand they may serve as useful carriers for 
hydrophobic photoactive molecules in biosystems and on the other hand, they may 
possess a high payload for targeting molecules. Among others, the photosensitizer 
mTHPC had been incorporated into different types of liposomes and successfully applied 
in PDT protocols in-vitro and in-vivo [5, 6, 8, 21-24]. However, the lack of information 
on molecular effects prompted us to explore cellular mechanisms in PDT with the 
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DDPG/DDPC liposomal mTHPC derivative Foslipos, using the prostate carcinoma cell 
line PC-3 as model.  
Our microscopic studies on the cellular uptake showed that Foslipos is quickly 
accumulating in the cytoplasm of PC-3 cells while always sparing the nucleus. We 
conclude that liposomal preparations do not affect the intracellular distribution since 
comparable patterns had been reported for mTHPC in a variety of human cell lines [25-
27].  
As shown before for PC-3-grafted mice [28], PC-3 cells are highly responsive for 
mTHPC-mediated PDT. Under our experimental conditions we repetitively observed an 
over 90% reduced cell count 24h after PDT with Foslipos compared to untreated controls. 
However, the kinetics of this reaction were not linear but rather characterized by a two-
step process with an initial death of cells, being already significant a few minutes after 
light application in PDT (i.e. at TP0) and a second - stronger - boost occuring more than 
5h later. Likely, the first “hit” is due to direct detrimental actions of short-lived reactive 
oxygen species (ROS), that are known to be generated in fractions of seconds after PDT 
and apparently kill a portion of cells immediately. However, the majority of cells seemed 
to be merely damaged by ROS and eventually undergo a death process that takes several 
hours. Whether the latter is related to apoptosis was not within the scope of our 
experiments and will be the focus of further studies.   
To investigate the mechanisms leading to the observed photodynamic effects in more 
detail we performed experiments to characterize damaging effects on nucleic acids. 
Results for DNA damage, RNA amount and integrity supports our above observation of 
an acute PDT effect, that can be documented already shortly after light application.    
Since we were unable to localize photosensitizer fluorescence to the cell nucleus, it was 
surprising that directly after PDT a significant number of DNA strand breaks due to base 
loss were already detectable. However, results may be explained by mechanisms similar 
to those observed in a murine glioma cell line, where mTHPC entered the nucleus during 
light application [29]. The profound and early DNA damage may account for instant cell 
destruction but – if not repaired - may also result in e.g. blocked DNA replication 
eventually leading to initiation of death cascades. Notably, even within 24h after PDT no 
recovery of the number of abasic sites (compared to TP1) was detected, indicating that no 
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DNA repair had been initiated. At the RNA level these results are complemented by the 
observation that several important genes associated with DNA repair mechanisms had 
been transcriptionally downregulated or destroyed after PDT with Foslipos. These 
include the early DNA damage sensor ATM, DDB1, that is a subunit of the damage-
specific DNA binding protein complex, the DNA excision repair endonucleases ERCC1 
and ERCC3, the postreplication DNA repair genes RAD23A and RAD50, the uracil-
DNA glycosylase UNG and the DNA double strand repair proteins XRCC1 and XRCC2. 
Furthermore, RNA for PCNA, that is involved in base-excision repair pathways, was 
reduced. However, low DNA repair capacities have dual effects: they confer a 
cytotoxicity favorable for PDT by triggering cell death but surviving cells are prone to 
mutations with unpredictable consequences. In worst case this may result in secondary 
malignancies after PDT. Our data are in accordance with those in murine gliobastoma 
cells where mTHPC-PDT also resulted in an immediate DNA damage, however, in this 
study and others activation of repair mechanisms after PDT had been reported [29-32]. 
Since our data are in contrast to in-vitro studies in human myeloid leukaemia and 
nasopharyngeal carcinoma cells where no DNA damage was found after mTHPC-PDT 
[33, 34], the observed effect may depend on cell line.  
The significantly lower readings at TP0 of RNA content per cell after PDT vs. all 
controls indicate that some RNA was initially destroyed, - presumably by an acute and 
direct effect of ROS on RNA and not by transcriptional regulation. Not unexpected, the 
major part of specific genes investigated here thus displayed lower transcript numbers 
after PDT. Since total RNA consists to 90-95% of ribosomal RNA (rRNA), our data may 
also point towards an impact of PDT on the translational machinery itself. Interestingly, 
illumination alone (IRR) lead to a significant increase of RNA amounts measured at 
TP24, so that actually an interaction of effects elicited by light on the one hand and ROS 
on the other hand may take place after PDT.  
Our further RNA expression studies focusing on established genes involved in stress and 
toxicity indicated a very complex molecular response of PC-3 cells to mTHPC-mediated 
PDT, including both higher or lower transcript levels of genes with the potential to either 
support or counter-act PDT actions. While a higher gene expression is due to an 
upregulation, lower expression scores may be either a sign of PDT-related RNA 
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destruction or of true downregulation. The latter may well be a consequence of the 
observed oxidative DNA damage after PDT. However, with regard to possible damage of 
rRNA in PDT it is far from clear whether upregulated transcripts are in fact translated 
into proteins.  
Our study reveals reduced levels of genes involved in cellular defense mechanisms 
against oxidative and metabolic stress. PDT with other photosensitizers are partly in 
accordance [35, 36] and partly in contrast to our data [37, 38]. Because CAT and SOD1 
have been shown to protect cells against phototoxic effects of hematophorphyrin 
derivative or ALA in vitro [39, 40] and inhibition of SODs results in increased PDT 
effects [41], we hypothesize that the reduced ability of the cells to cope with oxidative 
and metabolic stress may constitute an important mechanism for PDT effects with 
Foslipos. However, as in other studies [42, 43], we found that two antioxidant defense 
genes (CRYAB and HMOX1) were strongly upregulated. The small heat shock protein 
CRYAB and the heme oxygenase family member HMOX are known to act as anti-
apoptotic molecules that protect cells against oxidative damage [44]. Together with the 
observation that inhibition of HMOX may increase the efficacy of PDT [43, 45], we 
propose that – if translated - high levels of HMOX or CRYAB may eventually prevent 
optimal phototoxic effects.  
Expression patterns of heat-shock proteins (HSPs) in our study turned out to be very 
complex. Several previous papers reported the induction of HSP60, HSP70 or HSP90 
after PDT with various photosensitizers [46-51]. However, HSPs consist of large protein 
families and in our study we found that expression of members may be downregulated or 
upregulated after PDT with Foslipos. Upregulation of the HSP40 member DNAJB4 as 
well as HSP70 members HSPA1A, HSPA1L and especially HSPA6, that is only induced 
by severe stress-stimuli, may mirror the extent of damage in our model but also indicate 
the presence of a (partly) preserved stress-response system. On the other hand it should 
be noted that RNA levels of several HSP members investigated here are downregulated. 
Thus protective mechanisms by HSPs may be rather impaired after PDT with Foslipos. 
Notably, some of the downregulated HSP70 members belong to essential house keeping 
genes.  
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PDT with Foslipos may not only have direct destructive effects on cells but may also 
block proliferation and induce cell cycle arrest in survivors. Since cell damage is 
obviously so profound that repair mechanisms are not operative, death pathways are 
eventually activated. As reported in part previously [52-54], transcripts of cyclin family 
genes CCNC, CCND1 and CCNG1 as well as of PCNA, a protein crucial for DNA 
replication, were markedly reduced after PDT in our model thereby possibly leading to a 
diminished proliferative activity. However, the observed downregulation of cyclin-
interacting transcription factor E2F1 may also directly promote cell death, as reported 
previously for PC-3 cells [55]. The tumor suppressor p53 (TP53) is regarded as a key 
factor for the regulation of cell growth and death. Interestingly, we and others [56] found 
that PDT did not change the expression of this gene. However, the expression of one of 
the main targets of TP53, the cyclin-dependent kinase inhibitor CDKN1A, was reduced 
after PDT in our study, further supporting an impact of PDT on cell cycle processes. Our 
data are in contrast to PDT studies that report an increase in CDKN1A [57]. Since 
MDM2, an important inhibiting factor of p53, was reduced in our study, the ratio of 
MDM2 to TP53 apparently changed. This may be associated with the potential of 
increased p53-related pathways and/or reduced p53 degradation followed by cell cycle 
arrest and apoptosis. Furthermore, we found a strong upregulation of the bZIP 
transcription factor DDIT3 – notably independent of p53 - after PDT. Since DDIT3 had 
been implicated in anti-proliferative effects and the induction of apoptosis by certain anti-
cancer agents, including in PC-3 cells [58], the observed high levels may have also 
contributed to growth arrest and apoptotic signaling in our experiment after PDT.  
We here report a marked downregulation of IGFBP6 after PDT. Being a relatively 
specific inhibitor of IGF-II action, high levels of IGFBP-6 had been found to block 
proliferation and increase apoptosis in-vitro, including in PC-3 cells [59, 60].  
In our study, genes involved in apoptosis signaling all displayed reduced transcript 
numbers. Most of these genes seem to be damaged early – probably due to direct ROS 
effects. TNFRSF1A, that binds CASP8, as well as both the apoptosis-inducing ligands 
TNFSF10 and FASLG are almost completely shut down already at TP1 in our model. 
The biological consequences of fewer apoptosis-promoting BAX in addition to fewer 
anti-apoptotic BCL2L1 transcripts in PDT with Foslipos are not clear yet. Of interest is 
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the further reduction of CASP8 and CASP10 RNA over time that is suggestive of a PDT-
driven regulatory process. Since many of cell death processes are more adequately 
investigated at the protein level our data do not generally exclude the activation of 
apoptotic pathways in Foslipos-mediated PDT. The results may rather be another sign of 
a breakdown in basic cellular functions. 
 
Taken together, we propose that Foslipos-mediated PDT in PC-3 cells is characterized by 
a two-stage process. A significant number of cells is disintegrated within minutes, - a 
process that is likely driven by direct actions of ROS on vital biological components. 
Even in in-vitro systems that ought to contain a homogeneous population of cells and that 
uniformly accumulate the photosensitizer, the majority of cells survive this attack. Of 
course we cannot exclude that this is due to our experimental set-up with e.g. unequal 
illumination. However, initially surviving cells go into growth arrest and display signs of 
an oxidative stress response, while many transcripts whose proteins are known to 
contribute to cellular rescue mechanisms are reduced. Since this is in parallel to severe 
damages of genomic DNA and the translational system, cells are unable to recover and 
ultimately die after a delay of several hours.  
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Legends 
Fig. 1 
Dark toxicity in PC-3 cells: results of colony forming assays after incubation without or 
with 0.1-10 mg/ml Foslipos. * p>0.05% 
 
Fig. 2 
Uptake of Foslipos into PC-3 cells after (A) 15 min, (B) 1h, (C) 2h, (D) 3h, (E) 4h, and 
(F) 5h incubation with photosensitizer. Confocal laser scanning microscopy, bar denotes 
20 m. 
 
Fig. 3 
Effect of PDT with Foslipos on cell death: direct counts after trypan blue staining directly 
(TP0) and 1h (TP1), 2h (TP2), 5h (TP5) and 24h (TP24) after light application. CO: no 
treatment, IRR: with light application, FOS: with incubation of Foslipos.   
 
Fig. 4 
Estimation of DNA lesions: binding of an aldehyde reactive probe to DNA after PDT 
with Foslipos directly (TP0), 1h (TP1) and 24h (TP24) after light application. CO: no 
treatment, IRR: with light application, FOS: with incubation of Foslipos. Measurements 
in arbitrary units at O.D.460nm 
 
 
Fig. 5 
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RNA content in g per 100’000 cells after incubation with Foslipos directly (TP0) and 1h 
(TP1), 2h (TP2), 5h (TP5) and 24h (TP24) after light application (PDT). CO: no 
treatment, IRR: with light application, FOS: with incubation of Foslipos.   
 
Fig. 6 
(A) Effect of Foslipos-mediated PDT on RNA integrity directly (TP0) and 1h (TP1), 2h 
(TP2), 5h (TP5) and 24h (TP24) after light application (PDT). CO: no treatment, IRR: 
with light application, FOS: with incubation of Foslipos. Calculation of the RNA 
integrity number (RIN), where 10 is intact and 1 is disintegrated. (B) Virtual 
electrophoresis of total RNA after PDT with Foslipos directly after illumination (TP0) 
and 24h after light application (TP24). CO: no treatment, IRR: with light application, 
FOS: with incubation of Foslipos, M: molecular weight marker. Arrow and double arrow 
denote 28S rRNA and 18S rRNA, respectively. 
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